Brian Kim is a Dermatology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4901 Forest Park Ave
Div Im Dermatology, Ste 502
Saint Louis, MO 631081495
Telephone
314-273-3376Registry record last updated 12 Nov 2021.
Clinical trials
- Effectiveness of Bisacodyl Suppository Agent for Dose Reduction of Low Dose PEG
Sponsor: Samsung Medical Center
- A Study Examining the Medication Apremilast as Treatment for Chronic Itch
Sponsor: Washington University School of Medicine
- Relieving Chronic Itch: Oral Medication
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
33 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202514 payments$81,701openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year20256 payments$17,098openpaymentsdata.cms.gov ↗
- Galderma Laboratories, L.P.Program year202513 payments$15,881openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
47.9%Opioid Agonist/Antagonist28.1%Butorphanol Tartrate100%Part D<11 patientsGabapentinoids19.8%Gabapentin100%Part D<11 patientsDermatology
24%Interleukin-4 Receptor alpha Antagonist24%Dupixent Pen100%Part D<11 patientsCancer & immunology
14%Kinase inhibitor14%Opzelura100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”